Company Profile

Saneron CCEL Therapeutics Inc (AKA: CCel Bio-Therapies Inc)
Profile last edited on: 6/6/2019      CAGE: 44AD1      UEI: W62DAG7PKK18

Business Identifier: Gene and cell therapies for treatment of neurological and cardiac disordera
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

13014 North Dale Mabry Highwat Suite 266
Tampa, FL 33618
   (813) 977-7664
Location: Single
Congr. District: 14
County: Hillsborough

Public Profile

Saneron CCEL Therapeutics Inc. is a biotechnology research company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases lacking adequate treatment options. The company's patented technology includes U-CORD-CELL from umbilical cord blood, which is a stem cell technology, as well as SERT-CELL from Sertoli cells. A University of South Florida spin-out, Saneron-CCEL Therapeutics is a subsidiary of CRYO-CELL International, Inc. In late 2001 the firm had merged with Saneron Therapeutics, Inc., to become Saneron CCEL Therapeutics, Inc. The company has been granted patents in many countries throughout the world for the therapeutic use of sertoli cells. With intellectual property for human cord blood as a source of stem cells, Saneron is committed to providing readily available, non-controversial, ethically acceptable cells, both stem cells and other cell types, for cellular therapies. Saneron has patented and patent-pending technology relating to our platform technology of: * U-CORD-CELLTM - Umbilical cord blood * SERT-CELLTM - Sertoli cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $843,689
Project Title: Stem Cells for Treating Acute Stroke
2014 2 NIH $422,946
Project Title: Neurorestorative Therapy of Stroke with Hucbc in T2dm Rats
2012 2 NIH $2,733,003
Project Title: HUCBC modulation of Alzheimer-like pathology and behavioral changes
2010 1 NIH $176,926
Project Title: Neuroprotective Therapy of Stroke with Hucnc and Simvastatin
2008 1 NIH $96,315
Project Title: Transplantation of Umbilical Cord Blood Stem Cells in Ischemic Brain Injury

Key People / Management

  Don F Cameron -- Director, Co-Founder

  Jieli Chen

  Cyndy D Davis Sanburg -- Sr Vice President Research & Development

  Svitlana N Garbuzova-Davis

  Jim Holland -- Director

  Zubair Kazi -- Director

  Kevin Klein -- Senior Vice President, Corporate Initiatives

  Kevin Klein -- Senior Vice President, Corporate Initiatives

  Nicole A Kuzmin-Nichols -- COO

  Walter C Low

  William G Marshall

  Paul R Sanberg -- Chairman, Co-Founder

  Juan R Sanchez-Ramos

  Samuel Saporta

  Bernard R Skerkowski -- Director, Corporate Treasurer

  Jun Tan